| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |